Advancing Cardiovascular Drug Screening Using Human Pluripotent Stem Cell-Derived Cardiomyocytes

Area of Science:

• Cardiovascular Research
• Stem Cell Biology
• Pharmacology

Background:

• Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are valuable for cardiac studies but often immature.
• A lack of high-throughput methods limits their application in drug screening.

Purpose of the Study:

• To develop a high-throughput platform using hPSC-CMs for assessing drug cardiotoxicity and effectiveness.
• To validate the utility of mature hPSC-CMs in drug discovery and development.

Main Methods:

• Optimized differentiation and maturation protocols for hPSC-CMs.
• High-throughput calcium imaging to monitor intracellular calcium dynamics.
• Testing compounds for cardiotoxicity and effectiveness, including comparison with HEK293-hERG cells.

Main Results:

• Mature hPSC-CMs demonstrated suitability for drug testing applications.
• Cardiotoxic drugs (encainide, mibefradil, cetirizine) showed toxicity in hPSC-CMs, unlike in HEK293-hERG cells.
• The platform successfully assessed drug effectiveness using a model for long QT syndrome type 3.

Conclusions:

• Mature hPSC-CMs provide a physiologically relevant model for preclinical drug screening.
• This high-throughput platform enhances the assessment of both cardiotoxicity and drug efficacy.
• hPSC-CMs hold significant potential for advancing drug discovery and development.